What does FARMAFLEX do?

FARMAFLEX is a pharmacy in Antwerpen. Private Limited, started on 22 March 1987, 1 establishment.

What is the address of FARMAFLEX?

The registered office of FARMAFLEX is located at Santvoortbeeklaan 18, 2100 Antwerpen.

Is FARMAFLEX still active?

Yes. According to the CBE (31 October 2026) FARMAFLEX is active, legal situation “Normale toestand”, started on 22 March 1987.

Is FARMAFLEX registered on Peppol?

Yes, FARMAFLEX is registered on the Peppol network with ID 0208:0430701675.

What is the enterprise number of FARMAFLEX?

The enterprise number of FARMAFLEX is BE0430701675.

When was FARMAFLEX founded?

FARMAFLEX was founded on 22 March 1987.

Who are the directors of FARMAFLEX?

According to the 2025 annual accounts, the directors of FARMAFLEX are: CARMEN CHEUNG, WAI KWONG CHEUNG.

Is FARMAFLEX a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 22 March 1987; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did FARMAFLEX make in 2025?

FARMAFLEX posted a profit after taxes of € 578 in financial year 2025.

What is the revenue of FARMAFLEX?

As a small company, FARMAFLEX is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 30,263.

FARMAFLEX (Private Limited) - Antwerpen - BE0430701675

Dossier FARMAFLEX, printed on 31 October 2026 from databakkes.be/en/0430701675/farmaflex. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

FARMAFLEX from Antwerpen, company number BE0430701675, closed financial year 2025 with a result of € 578 after tax. For that financial year FARMAFLEX recorded a gross margin of € 30,263 and equity of € 151,191. Compared with financial year 2024, the result moved from € 9,811 to € 578. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 28, 2026.

What it is worth Growing

€ 151,191

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 578

▼ 94% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 9,005

▼ 69% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 22,286.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 163,727

▼ 20% vs 2024

€ 40,956 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 2,449

▲ € 2,254 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 230

▲ 1% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 25,300 Gross margin 2022: € 25,300 First fiscal year in the series	€ 41,037 Gross margin 2023: € 41,037 ▲ 62% vs 2022 (€ 25,300) Favourable step	€ 42,624 Gross margin 2024: € 42,624 ▲ 4% vs 2023 (€ 41,037) Favourable step	€ 30,263 Gross margin 2025: € 30,263 ▼ 29% vs 2024 (€ 42,624) Unfavourable step	▼ 29%
Profit after taxes	€ -18,058 Profit after taxes 2022: € -18,058 First fiscal year in the series	€ -1,393 Profit after taxes 2023: € -1,393 ▲ € 16,664 vs 2022 (€ -18,058) Favourable step	€ 9,811 Profit after taxes 2024: € 9,811 ▲ € 11,205 vs 2023 (€ -1,393) Favourable step	€ 578 Profit after taxes 2025: € 578 ▼ 94% vs 2024 (€ 9,811) Unfavourable step	▼ 94%
Equity	€ 142,195 Equity 2022: € 142,195 First fiscal year in the series	€ 140,802 Equity 2023: € 140,802 ▼ 1% vs 2022 (€ 142,195) Unfavourable step	€ 150,613 Equity 2024: € 150,613 ▲ 7% vs 2023 (€ 140,802) Favourable step	€ 151,191 Equity 2025: € 151,191 Unchanged (€ 150,613) Favourable step
Total debts	€ 297,558 Total debts 2022: € 297,558 First fiscal year in the series	€ 378,072 Total debts 2023: € 378,072 ▲ 27% vs 2022 (€ 297,558) Unfavourable step	€ 415,577 Total debts 2024: € 415,577 ▲ 10% vs 2023 (€ 378,072) Unfavourable step	€ 397,995 Total debts 2025: € 397,995 ▼ 4% vs 2024 (€ 415,577) Favourable step	▼ 4%
Cash	€ 34,549 Cash 2022: € 34,549 First fiscal year in the series	€ 7,033 Cash 2023: € 7,033 ▼ 80% vs 2022 (€ 34,549) Unfavourable step	€ 29,143 Cash 2024: € 29,143 ▲ € 22,110 vs 2023 (€ 7,033) Favourable step	€ 9,005 Cash 2025: € 9,005 ▼ 69% vs 2024 (€ 29,143) Unfavourable step	▼ 69%
Land & buildings	€ 203,840 Land & buildings 2022: € 203,840 First fiscal year in the series	€ 169,867 Land & buildings 2023: € 169,867 ▼ 17% vs 2022 (€ 203,840) Unchanged	€ 135,893 Land & buildings 2024: € 135,893 ▼ 20% vs 2023 (€ 169,867) Unchanged	€ 101,920 Land & buildings 2025: € 101,920 ▼ 25% vs 2024 (€ 135,893) Unchanged	▼ 25%
Retained profit	€ 13,291 Retained profit 2022: € 13,291 First fiscal year in the series	€ 11,897 Retained profit 2023: € 11,897 ▼ 10% vs 2022 (€ 13,291) Unfavourable step	€ 21,708 Retained profit 2024: € 21,708 ▲ 82% vs 2023 (€ 11,897) Favourable step	€ 22,286 Retained profit 2025: € 22,286 ▲ 3% vs 2024 (€ 21,708) Favourable step	▲ 3%
Bank debt	€ 283,209 Bank debt 2022: € 283,209 First fiscal year in the series	€ 243,934 Bank debt 2023: € 243,934 ▼ 14% vs 2022 (€ 283,209) Favourable step	€ 204,115 Bank debt 2024: € 204,115 ▼ 16% vs 2023 (€ 243,934) Favourable step	€ 163,727 Bank debt 2025: € 163,727 ▼ 20% vs 2024 (€ 204,115) Favourable step	▼ 20%
Balance sheet total	€ 439,753 Balance sheet total 2022: € 439,753 First fiscal year in the series	€ 518,873 Balance sheet total 2023: € 518,873 ▲ 18% vs 2022 (€ 439,753) Unchanged	€ 566,190 Balance sheet total 2024: € 566,190 ▲ 9% vs 2023 (€ 518,873) Unchanged	€ 549,186 Balance sheet total 2025: € 549,186 ▼ 3% vs 2024 (€ 566,190) Unchanged	▼ 3%

Key figures of FARMAFLEX, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to FARMAFLEX?

What happened at FARMAFLEX in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 28, 2026 New annual accounts for financial year 2025: profit of € 578 (▼ 94% vs 2024). Source: NBB ↗
2017 WAI KWONG CHEUNG became a director. NBB
2011 CARMEN CHEUNG became a director. NBB
Mar 25, 1987 New establishment in Antwerpen. KBO
Mar 22, 1987 Start of the company according to the CBE. KBO

In short

From € 18,058 loss in 2022 to € 578 profit in 2025.

Paid € 885 in corporate taxes since 2022.

Best year ever: 2024, with € 9,811 profit.

Original PDFs at the National Bank ↗

Management

NEW WORLD 100%

The stake of NEW WORLD comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

FARMAFLEX

Behind FARMAFLEX are CARMEN CHEUNG and WAI KWONG CHEUNG. The shares are held by NEW WORLD (100%).

Directors

According to the 2025 annual accounts

CARMEN CHEUNG

Director

Also active at: ACCORBEX - INVEST, SWATOW

since 2011

WAI KWONG CHEUNG

Director

Also active at: ACCORBEX - INVEST, NEW WORLD, SWATOW

since 2017

Shareholders

NEW WORLD

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Santvoortbeeklaan 18

2100 Antwerpen

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.

All companies at this address →

ACCORBEX - INVEST same network

€ 287,530 gross margin · 2025

NEW WORLD same network

€ 210,122 gross margin · 2025

PHARMA-C

Guanyu

€ 115,520 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0430.701.675

VAT number

BE 0430.701.675

Registered office

Santvoortbeeklaan 18, 2100 Antwerpen

Names & denominations

FARMAFLEX

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

22 March 1987

Peppol

Active · Active since 3 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van syndici van onroerend goed

Beheer van niet-residentieel onroerend goed voor een vast bedrag of op contractbasis

View on CBE Public ↗ Annual accounts (NBB) ↗

FARMAFLEX

Financials

What happened to FARMAFLEX?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions